| abstract |
The present disclosure relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non- immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well as specific nucleic acid constructs that are particularly suitable for the preparation of such compositions. |